A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs SLV 341 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Abbott Healthcare Products
- 22 Jul 2009 Planned number of patients changed from 110 to 87 as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Apr 2009 New trial record